Skip to main content

Another day, another bimekizumab (IL17i) study Across 2 trials, improved PsA specific QOL ("PsAID") metrics Nice to se

Nov 14, 2023 3:09 pm
Social Author Name
Mike Putman
Tweet Content
Another day, another bimekizumab (IL17i) study Across 2 trials, improved PsA specific QOL ("PsAID") metrics Nice to see focus on PROs & I always love a good spidergram @RheumNow #ACR23 Absr2249 https://t.co/dsLXstPzt2
Show on Archive Page
On
Display in Search Results
On
PDQ
Off
×